Finance

Lists
Why is MRK up 2,82%?
Dive Deeper
MRK:NYSE
Merck & Co Inc
USD 146,40
+2,82%
(+4,02) 1D
9 Okt., 14:02:39 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRK...
Open
USD 141,37
High
USD 146,68
Low
USD 141,36
Mkt. cap
361,19 mjd
Avg. vol.
9,40 m
Volume
4,05 m
Dividend
2,32%
Quarterly dividend
USD 0,85
Ex-dividend date
15 Sep. 2026
P/E ratio
116,93
52-wk high
USD 156,92
52-wk low
USD 82,01
EPS
USD 1,25
Beta
0,21
Shares outstanding
2,47 mjd
No. of employees
74 k
Open
USD 141,37
High
USD 146,68
Low
USD 141,36
Mkt. cap
361,19 mjd
Avg. vol.
9,40 m
Volume
4,05 m
Dividend
2,32%
Quarterly dividend
USD 0,85
Ex-dividend date
15 Sep. 2026
P/E ratio
116,93
52-wk high
USD 156,92
52-wk low
USD 82,01
EPS
USD 1,25
Beta
0,21
Shares outstanding
2,47 mjd
No. of employees
74 k
News stories
From web sources and news partners
Profile
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
About Merck & Co Inc
CEORobert M Davis
Employees74 k
Founded01 Jan. 1891
Headquarters-
SectorPharmaceutical industry
Websitemerck.com
Analyst ratings
Based on 21 analysts giving stock ratings to MRK in the past 3 months
Buy
Buy
14
Hold
7
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for MRK in the last 3 months.
Highest
Current USD 146,40
USD 180,00 (+22,95%)
Average
USD 160,40 (+9,56%)
Lowest
USD 105,00 (-28,28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Yee
UBS
Buy
Maintained
USD 175,00
+19,5%
10/09/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
USD 163,00
+11,3%
10/09/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
USD 170,00
+16,1%
10/08/2026
Carter Gould
Cantor Fitzgerald
Hold
Reiterated
USD 145,00
-1%
10/08/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
USD 177,00
+20,9%
10/07/2026
Chris Schott
J.P. Morgan
Buy
Maintained
USD 165,00
+12,7%
10/05/2026
Asad Haider
Goldman Sachs
Buy
Maintained
USD 160,00
+9,3%
09/30/2026
Louise Chen
Scotiabank
Buy
Maintained
USD 180,00
+23%
09/29/2026
Geoff Meacham
Citi
Hold
Maintained
USD 125,00
-14,6%
09/29/2026
Trung Huynh
RBC Capital
Hold
Maintained
USD 150,00
+2,5%
09/29/2026
Steve Scala
TD Cowen
Hold
Maintained
USD 155,00
+5,9%
09/22/2026
Nico Chen
DBS
Buy
Maintained
USD 180,00
+23%
09/11/2026
Rajesh Kumar
HSBC
Buy
Maintained
USD 172,00
+17,5%
09/10/2026
Daina Graybosch
Leerink Partners
Buy
Reiterated
USD 161,00
+10%
09/10/2026
Vamil Divan
Guggenheim
Buy
Reiterated
USD 170,00
+16,1%
09/08/2026
Emily Field
Barclays
Hold
Reiterated
€150,00
+2,5%
09/07/2026
Courtney Breen
Bernstein
Hold
Maintained
USD 105,00
-28,3%
09/07/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
USD 170,00
+16,1%
09/04/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
USD 170,00
+16,1%
08/24/2026
Alexandria Hammond
Wolfe Research
Buy
Maintained
USD 180,00
+23%
08/25/2026
Luisa Hector
Berenberg Bank
Hold
Maintained
USD 127,00
-13,3%
08/05/2026
Unknown Analyst
Jefferies
Buy
Maintained
USD 138,00
-5,7%
05/19/2026
Unknown Analyst
Argus Research
Buy
Reiterated
USD 130,00
-11,2%
05/08/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Natalya Davies
Rothschild & Co Redburn
Buy
Maintained
USD 179,00
+22,3%
04/17/2026
James Shin
Deutsche Bank
Buy
Upgraded
USD 150,00
+2,5%
02/13/2026
Last report
04 Aug. 2026
Fiscal period
Q2 2026
-USD 0,13 / -USD 0,26
+49,43%beat
Revenue / Est. (USD)
16,61 mjd / 16,37 mjd
+1,46%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
17,28 mjd
16,40 mjd
16,29 mjd
16,61 mjd
Cost of goods sold
3,74 mjd
4,30 mjd
3,88 mjd
4,13 mjd
Cost of revenue
3,74 mjd
4,30 mjd
3,88 mjd
4,13 mjd
Research and development expenses
4,00 mjd
4,00 mjd
3,56 mjd
9,74 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,48 mjd
2,73 mjd
2,57 mjd
2,78 mjd
Operating expense
6,48 mjd
6,73 mjd
6,12 mjd
12,52 mjd
Total operating expenses
10,23 mjd
11,02 mjd
10,00 mjd
16,65 mjd
Operating income
7,05 mjd
5,38 mjd
6,29 mjd
-40,00 m
Other non operating income
-
41,00 m
42,00 m
59,00 m
EBT including unusual items
6,74 mjd
3,42 mjd
-3,53 mjd
-683,00 m
EBT excluding unusual items
6,76 mjd
4,98 mjd
5,85 mjd
-508,00 m
Income tax expense
958,00 m
458,00 m
709,00 m
654,00 m
Effective tax rate
14,20%
13,39%
-20,06%
-95,75%
Other operating expenses
-
-
-
-
Net income
5,78 mjd
2,96 mjd
-4,24 mjd
-1,34 mjd
Net profit margin
33,49%
18,07%
-26,03%
-8,04%
Earnings per share
2,58
2,04
-1,28
-0,13
Interest and investment income
96,00 m
69,00 m
35,00 m
35,00 m
Interest expense
-327,00 m
-411,00 m
-479,00 m
-525,00 m
Net interest expenses
-231,00 m
-342,00 m
-444,00 m
-490,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
8,15 mjd
6,79 mjd
7,69 mjd
1,43 mjd
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme